Lancaster Capital
2 Lancaster Crescent, Glasgow, Scotland, G12 0RR, United Kingdom
Overview
Lancaster Capital is an early stage equity investment fund based in Scotland. They invest in people with exciting ideas for new businesses. They invest alongside such people by way of equity in the companies they start up. It's the simplest of co-operations – they enable money and these exciting business ideas to come together to create successful enterprises and wealth. They prefer to invest in new and protected technology which will perform some useful function. It will be important to them that the company they invest in does own that technology. Naturally, they favour new businesses with high growth potential. Lancaster Capital is a private fund and not an angel syndicate. They act however as a hub for a number of like minded private investors most of whom have had substantial success in building their own businesses. Their singular aim when investing together is to make good equity investments.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Finance
- Financial Services
Investment portfolio
- Curapel
Participated · Equity · May 2016
Curapel is a Cardiff, Wales–based healthcare company spun out of the University of Manchester and led by CEO Dr Peter Luebcke with CTO Dr Neil Gibbs. The company develops treatments for eczema and psoriasis and products for skin pigmentation conditions. Its pipeline includes Histimex (an oral treatment with early clinical potential in eczema and atopic dermatitis, including pediatric eczema), Melidex (a cosmetic product to even skin tone and treat pigmentation), and Olidex (a topical treatment for psoriasis). Products are formulated from safe, natural and GRAS-designated ingredients and are patent protected. All products are in late-stage product development with clinical testing scheduled to continue through 2016. Curapel is using new funding to develop and commercialise the Histimex, Melidex and Olidex product portfolio.
Team
No current team members are available.